慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌

doi:10.3969/j.issn.1672-5069.2023.03.037

Abstract

Abstract: With the increasing prevalence of obesity and diabetes, the incidence of nonalcoholic fatty liver diseases(NAFLD)has gradually increased. More and more patients with chronic hepatitis B (CHB) are complicated with NAFLD. The chronic HBV infection and NAFLD are both causes of hepatocellular carcinoma(HCC), and the patients with CHB and NAFLD might have the increased risk of HCC. In this article, we review the hepatocarcinogenesis, prevention and control management of patients with CHB and NAFLD, and patients with HCC.

Key words: Hepatocellular carcinoma, Hepatitis B, Nonalcoholic fatty liver diseases, Pathogenesis, Management

Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases?[J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.

References

[1] Hui RWH, Seto WK, Cheung KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. J Viral Hepat, 2018, 25(1): 97-104.
[2] Yang J, Chen X, Zhang H, et al. HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma. J Med Virol, 2014, 86(6): 913-917.
[3] Kao JH, Chen PJ, Lai MY, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology, 2003, 124(2): 327-334.
[4] Park YM, Jang JW, Yoo SH, et al. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat, 2014, 21(3): 171-177.
[5] Zhang Y, Yan Q, Gong L, et al. C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene, 2021, 40(6): 1147-1161.
[6] Mao X, Tey SK, Ko FCF, et al. C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Lett, 2019, 444: 60-69.
[7] Toh ST, Jin Y, Liu L, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis, 2013, 34(4): 787-798.
[8] Jiang Y, Han Q, Zhao H, et al. The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcinoma, 2021, 8: 435-450.
[9] Cougot D, Wu Y, Cairo S, et al. Correction: The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem, 2020, 295(9): 2888.
[10] Martin-Lluesma S, Schaeffer C, Robert EI, et al. Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1. Hepatology, 2008, 48(5): 1467-1476.
[11] Liu H, Shi W, Luan F, et al. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus genes, 2010, 40(2): 174-182.
[12] Mohammadizad H, Shahbazi M, Hasanjani Roushan MR, et al. TIM-3 as a marker of exhaustion in CD8(+) T cells of active chronic hepatitis B patients. Microb Pathog, 2019, 128: 323-328.
[13] Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut, 2019, 68(5): 916-927.
[14] Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology, 2007, 132(7): 2328-2339.
[15] Peppa D, Micco L, Javaid A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog, 2010, 6(12): e1001227.
[16] De Minicis S, Agostinelli L, Rychlicki C, et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PloS One, 2014, 9(5): e97136.
[17] Kudo Y, Tanaka Y, Tateishi K, et al. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol, 2011, 55(6): 1400-1408.
[18] Chettouh H, Lequoy M, Fartoux L, et al. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int, 2015, 35(10): 2203-2217.
[19] Sorrentino P, D'angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol, 2009, 50(2): 351-357.
[20] He G, Karin M. NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res, 2011, 21(1): 159-168.
[21] Ding J, Zhao J, Huan L, et al. Inflammation-induced long intergenic noncoding RNA (LINC00665) increases malignancy through activating the double-stranded RNA-activated protein kinase/nuclear factor Kappa B pathway in hepatocellular carcinoma. Hepatology, 2020, 72(5): 1666-1681.
[22] Huang H, Zhang J, Ling F, et al. Leptin receptor (LEPR) promotes proliferation, migration, and invasion and inhibits apoptosis in hepatocellular carcinoma by regulating ANXA7. Cancer Cell Int, 2021, 21(1): 4.
[23] Stefanou N, Papanikolaou V, Furukawa Y, et al. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC cancer, 2010, 10: 442.
[24] Sharma D, Wang J, Fu PP, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology, 2010, 52(5): 1713-1722.
[25] Xing SQ, Zhang CG, Yuan JF, et al. Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins. Biochem Pharmacol, 2015, 93(2): 221-231.
[26] Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531(7593): 253-257.
[27] Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8⁺ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer cell, 2014, 26(4): 549-564.
[28] Chan AW, Wong GL, Chan HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol, 2017, 32(3): 667-676.
[29] Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology, 2020, 71(2): 539-548.
[30] Pereira Tde A, Witek RP, Syn WK, et al. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest, 2010, 90(12): 1690-1703.
[31] Rangwala F, Guy CD, Lu J, et al. Increased production of sonic Hedgehog by ballooned hepatocytes. J Pathol, 2011, 224(3): 401-410.
[32] Liang H, Liu Y, Jiang X, et al. Impact of hepatic steatosis on the antiviral effects of PEG-IFNα-2a in patients with chronic hepatitis B and the associated mechanism. Gastroenterol Res Pract, 2020, 2020: 1794769.
[33] Jin X, Chen YP, Yang YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PloS One, 2012, 7(3): e34198.

Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases?

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qiu Liying, Wang Yingchun. Nonalcoholic fatty liver diseases and the intestinal microecology: Current state of the art, controversies, and perspectives [J]. Journal of Practical Hepatology, 2023, 26(3): 308-312.
[2]	Tao Zhenzhen, Wang Yongli, Sun Hongyan, et al.. Comparison of different Young's modulus determination by two-dimensional shear wave elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 328-331.
[3]	Zhao Jing, He Xiubo, Chen Jinhuan. Early diagnosis of significant liver fibrosis by liver shear wave elastography and GGT/PLT ratio in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 332-335.
[4]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[5]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.
[6]	Zhan Qirui, Duan Taimei, Yan Jie. Changes of serum amyloid A, plasma heme oxygenase-1 and bone morphogenetic protein 9 levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 348-351.
[7]	Fang Huijing, Zhu Chuanlong, Zhang Lili. Perspective on host-targeted therapeutic antiviral strategies for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 449-452.
[8]	Chen Peng, Liu Huan, Xu Liang. Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2023, 26(3): 453-456.
[9]	Fu Xin, Liu Yue, Peng Xin, et al.. Screening of occult hepatitis B viral infection in unpaid blood donors with low-level viremia by serum HBV DNA precise detection technology [J]. Journal of Practical Hepatology, 2023, 26(2): 169-172.
[10]	Yin Wen, Lu Kexiang, Wang Xue, et al.. Short-term efficacy of oxymatrine and entecavir combination in the treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(2): 173-176.
[11]	Yang Xiaolei, Chi ZhenJing, Sun Yimian, et al.. Prevention of mother-to-child transmission of hepatitis B virus in pregnant women with high serum HBV loads by oral tenofovir, and human hepatitis B immunoglobulin and hepatitis B vaccine combination immunization in fetus [J]. Journal of Practical Hepatology, 2023, 26(2): 177-180.
[12]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[13]	Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.
[14]	Wu Peng, Gao Liucun, Tang Shanhong. Artificial intelligence in the diagnosis and treatment of patients with liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 293-296.
[15]	Li Yangzhou, Lu Shuang. Hepatitis B virus reactivation during biologics therapy [J]. Journal of Practical Hepatology, 2023, 26(2): 297-300.